Stock listing

NYSE American:KAPA Kairos Pharma, Ltd. Stock

Home listing (NYSE American) of Kairos Pharma, Ltd.

Follow Kairos Pharma, Ltd. into a list and get an email when it puts out news.

Share price · AMEX:KAPA

$0.436 USD -0.004 (-1.0%)

Close on Nov 20, 2026

Past year -90.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.410 – $0.473 USDNov 20, 2026
Volume
33,061 sharesNov 20, 2026
Market cap
$1.48M USDAt the close on Nov 20, 2026 · price × 3.39M shares outstanding
52-week range
$0.381 – $7.280 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$374,614 USDMedian day 64,961 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Kairos Pharma, Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:KAPA · Home$0.436 USD-0.004 (-1.0%)33,061$0.473$0.473$0.410$0.440Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:KAPA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.436-0.004-1.0%$0.473$0.473$0.41033,061
$0.440+0.040+10.1%$0.400$0.540$0.400119,853
$0.400-0.007-1.7%$0.407$0.408$0.38120,498
$0.407-0.047-10.3%$0.424$0.454$0.40712,719
$0.454-0.027-5.6%$0.500$0.500$0.45312,521
$0.481-0.029-5.7%$0.503$0.510$0.48030,953
$0.510+0.036+7.6%$0.500$0.510$0.47420,226
$0.474-0.031-6.1%$0.510$0.519$0.47182,392
$0.505+0.017+3.5%$0.489$0.530$0.48934,789
$0.488+0.033+7.3%$0.494$0.495$0.48226,761
$0.455-0.035-7.2%$0.520$0.520$0.42472,813
$0.490-0.015-3.0%$0.510$0.530$0.49043,613
$0.505+0.032+6.7%$0.470$0.505$0.418195,423
$0.474-0.057-10.7%$0.541$0.541$0.47494,170
$0.530-0.010-1.9%$0.540$0.550$0.52547,378
$0.540+0.017+3.2%$0.536$0.576$0.525116,415
$0.523-0.007-1.3%$0.543$0.560$0.52364,961
$0.530-0.006-1.1%$0.525$0.553$0.52533,960
$0.536-0.023-4.1%$0.571$0.580$0.53666,398
$0.559+0.015+2.8%$0.544$0.590$0.530112,300
$0.544-0.033-5.7%$0.585$0.600$0.54383,000
$0.577-0.007-1.2%$0.566$0.617$0.565164,100
$0.584+0.014+2.5%$0.558$0.603$0.530153,500
$0.570-0.031-5.2%$0.624$0.628$0.522233,800
$0.601-0.070-10.4%$0.692$0.692$0.601134,400
$0.671-0.072-9.7%$0.721$0.731$0.656253,200
$0.743-0.086-10.4%$0.804$0.804$0.711285,500
$0.829-0.003-0.4%$0.832$0.839$0.783155,300
$0.832+0.022+2.7%$0.815$0.839$0.740251,000
$0.810-0.150-15.6%$0.911$1.004$0.783637,800
$0.960+0.090+10.3%$0.930$1.250$0.9155,820,700
$0.870-0.280-24.3%$1.090$1.140$0.8481,098,900
$1.150-0.400-25.8%$1.590$2.160$1.0609,944,600
$1.550-0.010-0.6%$1.550$1.590$1.52019,100
$1.5600.0000.0%$1.610$1.620$1.53525,800
$1.560-0.080-4.9%$1.590$1.650$1.47079,100
$1.640-0.020-1.2%$1.710$1.780$1.60099,300
$1.660-0.020-1.2%$1.680$1.755$1.64050,900
$1.680-0.040-2.3%$1.740$1.798$1.65051,800
$1.720-0.050-2.8%$1.770$1.780$1.72042,300
$1.770+0.040+2.3%$1.700$1.820$1.695299,900
$1.730-0.050-2.8%$1.750$1.778$1.70063,400
$1.780-0.010-0.6%$1.780$1.810$1.700247,100
$1.790+0.060+3.5%$1.750$1.800$1.700126,400
$1.730-0.080-4.4%$1.810$1.840$1.720168,700
$1.8100.0000.0%$1.840$1.840$1.78033,400
$1.810-0.040-2.2%$1.840$1.840$1.8105,300
$1.850+0.010+0.5%$1.790$1.890$1.76037,600
$1.840+0.082+4.7%$1.700$1.860$1.70053,500
$1.758+0.078+4.6%$1.687$1.765$1.67033,000
$1.680+0.020+1.2%$1.690$1.730$1.62132,600
$1.660-0.110-6.2%$1.760$1.800$1.66081,400
$1.770-0.070-3.8%$1.850$1.890$1.770173,400
$1.840+0.170+10.2%$1.670$1.910$1.660302,400
$1.670+0.090+5.7%$1.550$1.690$1.55047,600
$1.580-0.070-4.2%$1.610$1.650$1.510105,300
$1.650-0.030-1.8%$1.720$1.850$1.52076,300
$1.680+0.021+1.3%$1.687$1.750$1.6387,559
$1.659-0.028-1.7%$1.708$1.743$1.6244,543
$1.687-0.133-7.3%$1.883$1.883$1.5758,967
$1.820+0.084+4.8%$1.764$1.897$1.72913,694
$1.736+0.112+6.9%$1.701$1.750$1.6387,292
$1.624-0.406-20.0%$1.806$1.806$1.54035,200
$2.030-0.035-1.7%$2.030$2.107$2.0236,073
$2.065-0.105-4.8%$2.163$2.240$2.0445,073

Splits

1 split · AMEX:KAPA · every price before a split is adjusted for it

DayRatioWhat
1-for-7Consolidation
Ticker
NYSE American:KAPA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Kairos Pharma, Ltd. news

Kairos Pharma, Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 30 in all · newest Nov 5, 2026 · oldest 2025
Decks
7 decks · latest Nov 3, 2026

Where Kairos Pharma, Ltd. is listed

ListingExchangeCountryCurrency
NYSE American:KAPA · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:KAPABOATSUnited StatesUSD

Valuation

Price/book 0.4× against a median of 0.2×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$1.65M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.36

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kairos Pharma, Ltd. · AMEX:KAPAUS$1.48M−US$1.65Mn/an/an/a0.4×n/a0.0×1.36
SOHM, Inc. · OTC:SHMNUS$1.74MUS$4.99Mn/a5.5×n/a0.5×−28.1%0.9×-0.10
PRF Technologies Ltd. · NASDAQ:PRFXUS$1.66M−US$9.82Mn/a−249×n/a0.1×n/a0.0×1.93
Jupiter Neurosciences, Inc. · NASDAQ:JUNSUS$1.63MUS$1.33Mn/a16.9×n/an/an/an/a1.88
BioRestorative Therapies, Inc. · NASDAQ:BRTXUS$1.45M−US$2.11Mn/a−5.9×n/a0.5×n/a0.0×1.81
Nutra Pharma Corp. · OTC:NPHCUS$1.43MUS$13.99Mn/a87.0×n/an/an/an/an/a
Aptevo Therapeutics Inc. · NASDAQ:APVOUS$1.40M−US$2.88Mn/an/an/a0.4×n/a1.0×0.93
Agentix Corp. · OTC:AGTXUS$1.35MUS$1.34Mn/an/an/an/an/an/a-0.73
Clearmind Medicine Inc. · NASDAQ:CMNDUS$1.33M−US$9.01Mn/an/an/a0.2×n/a0.0×0.29
Artelo Biosciences, Inc. · NASDAQ:ARTLUS$1.30MUS$1.34Mn/an/an/a0.2×n/a0.0×1.36
International Stem Cell Corporation · OTC:ISCOUS$1.28M−US$18.76M0.1×−2.0×n/a0.1×222.6%0.0×-0.52
Median of the othersUS$1.42M−US$390,4810.1×1.7×0.2×97.3%0.0×0.93

Forecasts

1 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
49.00 USD · Analysts' mean
EPS, year to Dec 2026
-2.59 · 1 analyst

Team and board

Officers

OfficerRole
John S. YuCEO & Chairman
Doug SamuelsonChief Financial Officer
Ramchandran MuraliVP, Research and Development
Neil BhowmickChief Scientific Officer

Board

DirectorRole
John S. YuCEO & Chairman
Hyun W. Bae
Michael Keyoung
Rahul Singvhi

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−10.3%
Q2 2026Aug 12, 2026 · After close+1.4%
Q1 2026Jun 3, 2026−0.4%
Q4 2025Mar 31, 2026 · After close+3.6%
Q3 2025Nov 14, 2025 · After close−6.4%
Q2 2025Aug 12, 2025 · After close−4.5%
Q1 2025Apr 15, 2025 · After close−7.8%
Q4 2024Feb 26, 2025+6.1%
Q3 2024Nov 14, 2024 · After close−24.6%
Q2 2024Aug 28, 2024

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (November 2026)Technical22 slidesNov 3, 2026
Investor Presentation (September 2026)Investor deck25 slidesSep 14, 2026
Investor Presentation (May 2026)Investor deck32 slidesMay 18, 2026
Investor Presentation (2026)Investor deck25 slides2026
Corporate Update (September 2025)Corporate update7 slidesSep 18, 2025
Investor Presentation (March 2025)Investor deck24 slidesMarch 2025
Investor Presentation (October 2024)Investor deck25 slidesOct 10, 2024

Open Decks

IPO

Priced at US$4.00 a share on Sep 16, 2024.

Price
US$4.00 a share
Shares offered
1,550,000 shares of common stock
Offering size
US$6.2 million
Underwriters' option
Up to 232,500 more shares
Listing
KAPA on NYSE American
Underwriters
Boustead Securities, LLC, EF Hutton LLC, Sutter Securities, Inc. · In the order on the cover
Shares delivered
On or about Sep 17, 2024

Steps

StepWhen
Draft sent to the SEC in confidenceMar 29, 2023
Filed publiclySep 29, 2023
Amended 8 timesNewest Aug 16, 2024
Shares registered with an exchangeSep 12, 2024
Declared effective by the SECSep 16, 2024
Final prospectus, with the priceSep 17, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Sep 17, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue000000
Cost of revenue160.0K160.0K160.0K98.0K
Gross profit-160.0K-160.0K-160.0K-98.0K
Research and development2.13M414.0K82.0K87.0K183.0K20.0K
Selling, general and administrative3.44M1.93M1.47M324.0K1.66M1.03M
Operating income-5.57M-2.34M-1.71M-571.0K-1.94M-1.05M
Depreciation and amortization160.0K160.0K160.0K160.0K98.0K0
EBITDA-5.41M-2.18M-1.55M-411.0K-1.84M-1.05M
Interest expense035.0K42.0K479.0K202.0K5.41K
Income before tax-5.45M-2.60M-1.81M-1.05M-2.15M-1.05M
Income tax-2.60M
Net income-5.45M-2.60M-1.81M-1.05M-2.15M-1.05M
Earnings per share, basic-0.30-0.23-0.17-0.72-1.17-0.66
Earnings per share, diluted-0.30-0.23-0.17

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents4.49M1.27M93.0K437.0K73.0K14.3K
Current assets5.39M4.17M101.0K437.0K73.0K14.3K
Total assets6.54M5.77M965.0K1.04M775.0K14.3K
Accounts payable199.0K992.0K2.40M1.63M1.55M307.1K
Current liabilities199.0K992.0K2.40M1.63M1.94M357.1K
Long-term debt638.0K582.0K
Total debt638.0K586.0K380.0K50.0K
Total liabilities199.0K992.0K3.04M2.21M1.94M357.1K
Shareholders' equity6.34M4.78M-2.08M-1.18M-1.17M-342.8K
Shares outstanding2.97M13.7M10.6M1.46M1.83M1.60M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-3.44M-3.96M81.0K-353.0K-412.0K-38.5K
Capital spending00000-5
Free cash flow-3.44M-3.96M81.0K-353.0K-412.0K-38.5K
Cash from investing-109.0K
Cash from financing6.66M5.13M-425.0K717.0K580.0K37.0K
Change in cash3.22M1.18M-344.0K364.0K59.0K-1.53K

Open Financials

Filings

FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementNov 20, 2026Meeting noticeSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026Current reportSEC
8-K · Current reportNov 3, 2026Material contractSEC
8-K · Current reportOct 6, 2026Current reportSEC
8-K · Current reportSep 14, 2026Current reportSEC
8-K · Current reportAug 21, 2026Current reportSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportJul 22, 2026Material contractSEC
8-K · Current reportJul 15, 2026Current reportSEC
All 127 filings
FilingDateTypeFiled with
8-K · Current reportJun 30, 2026Meeting outcomeSEC
8-K · Current reportJun 4, 2026Current reportSEC
DEFA14A · Additional proxy materialMay 26, 2026Meeting noticeSEC
ARS · Annual report to shareholdersMay 22, 2026Annual reportSEC
DEF 14A · Proxy statementMay 22, 2026Meeting noticeSEC
8-K · Current reportMay 18, 2026Current reportSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
PRE 14A · Preliminary proxy statementMay 11, 2026Meeting noticeSEC
424B3 · ProspectusApr 1, 2026Offer documentSEC
424B3 · ProspectusApr 1, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 2, 2026Material contractSEC
8-K · Current reportFeb 26, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJan 26, 2026Other filingsSEC
CORRESP · Letter to the SECJan 21, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 15, 2026Other filingsSEC
S-3 · Registration statementJan 12, 2026Offer documentSEC
4 · Change in ownershipDec 30, 2025Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
4 · Change in ownershipNov 26, 2025Insider tradeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportOct 15, 2025Management or board changeSEC
8-K · Current reportOct 7, 2025Material contractSEC
8-K · Current reportSep 18, 2025Current reportSEC
8-K · Current reportSep 11, 2025Current reportSEC
8-K · Current reportSep 3, 2025Current reportSEC
424B3 · ProspectusAug 19, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
10-K/A · Annual report, amendedJul 28, 2025Annual reportSEC
8-K · Current reportJul 15, 2025Current reportSEC
8-K · Current reportJun 12, 2025Material contractSEC
8-K · Current reportJun 3, 2025Current reportSEC
DEFR14AMay 16, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
PRER14AMay 6, 2025Other filingsSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
3 · Initial statement of ownershipApr 30, 2025Insider tradeSEC
10-K/A · Annual report, amendedApr 28, 2025Annual reportSEC
8-K · Current reportApr 28, 2025Current reportSEC
424B3 · ProspectusApr 25, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 25, 2025Other filingsSEC
8-K · Current reportApr 24, 2025Current reportSEC
CORRESP · Letter to the SECApr 22, 2025Other filingsSEC
S-1 · Registration statementApr 21, 2025Offer documentSEC
10-K · Annual reportApr 15, 2025Annual reportSEC
4 · Change in ownershipApr 7, 2025Insider tradeSEC
NT 10-K · Late filing noticeMar 28, 2025Explanation requestSEC
8-K · Current reportMar 20, 2025Current reportSEC
8-K · Current reportFeb 26, 2025Current reportSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
DEF 14CFeb 10, 2025Meeting noticeSEC
8-K · Current reportFeb 6, 2025Current reportSEC
424B3 · ProspectusFeb 5, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 5, 2025Other filingsSEC
CORRESP · Letter to the SECJan 31, 2025Other filingsSEC
UPLOAD · Letter from the SECJan 31, 2025Other filingsSEC
PRE 14CJan 29, 2025Meeting noticeSEC
S-1 · Registration statementJan 29, 2025Offer documentSEC
DJan 28, 2025Other filingsSEC
8-K · Current reportJan 17, 2025Material contractSEC
8-K · Current reportJan 14, 2025Material contractSEC
UPLOAD · Letter from the SECJan 6, 2025Other filingsSEC
DRS · Draft registration statementJan 3, 2025Offer documentSEC
8-K · Current reportDec 13, 2024Management or board changeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 25, 2024Insider tradeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
8-K · Current reportNov 19, 2024Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportOct 10, 2024Current reportSEC
8-K · Current reportOct 4, 2024Material contractSEC
S-8 · Registration statement for employee plansSep 27, 2024Offer documentSEC
8-K · Current reportSep 27, 2024Material contractSEC
3 · Initial statement of ownershipSep 24, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 24, 2024Insider tradeSEC
8-K · Current reportSep 24, 2024Material contractSEC
8-K · Current reportSep 17, 2024Material contractSEC
424B4 · ProspectusSep 17, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 17, 2024Other filingsSEC
CORRESP · Letter to the SECSep 13, 2024Other filingsSEC
CORRESP · Letter to the SECSep 13, 2024Other filingsSEC
CORRESP · Letter to the SECSep 13, 2024Other filingsSEC
CERT · Exchange's certificate of listingSep 12, 2024Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeSep 12, 2024Other filingsSEC
CORRESP · Letter to the SECSep 9, 2024Other filingsSEC
CORRESP · Letter to the SECSep 9, 2024Other filingsSEC
S-1/A · Registration statement, amendedAug 16, 2024Offer documentSEC
CORRESP · Letter to the SECJun 3, 2024Other filingsSEC
S-1/A · Registration statement, amendedJun 3, 2024Offer documentSEC
S-1/A · Registration statement, amendedMay 24, 2024Offer documentSEC
S-1/A · Registration statement, amendedMay 20, 2024Offer documentSEC
S-1/A · Registration statement, amendedMay 10, 2024Offer documentSEC
S-1/A · Registration statement, amendedApr 30, 2024Offer documentSEC
S-1/A · Registration statement, amendedFeb 14, 2024Offer documentSEC
S-1/A · Registration statement, amendedDec 6, 2023Offer documentSEC
S-1 · Registration statementSep 29, 2023Offer documentSEC
DRSLTR · Letter to the SEC with a draftSep 15, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedSep 15, 2023Offer documentSEC
UPLOAD · Letter from the SECJul 6, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftJun 28, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedJun 28, 2023Offer documentSEC
DRS/A · Draft registration statement, amendedJun 28, 2023Offer documentSEC
DApr 26, 2023Other filingsSEC
UPLOAD · Letter from the SECApr 25, 2023Other filingsSEC
DRS · Draft registration statementMar 28, 2023Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Kairos Pharma, Ltd.’s releases

Common shares
3,385,383
Fully diluted
3,385,383

Fully diluted

LineShares
Common shares3,385,383

Share count over time

CountShares
Nov 22, 20263,385,383
Aug 21, 2026

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Vanguard Institutional Total Stock Market Index Fund164K3.5%US$62,901Jun 30, 2026
Fidelity Extended Market Index Fund81,1511.7%US$41,338May 31, 2026
Vanguard Extended Market Index Fund67,9441.5%US$26,070Jun 30, 2026
Fidelity Series Total Market Index Fund7,5990.16%US$3,871May 31, 2026
Blackstone Alternative Multi-Strategy Fund35<0.01%US$13Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Hansoo Michael Keyoung
Other companies: CalciMedica, Inc. (Director · Sep 24, 2020 – Sep 29, 2020 · Past)
Director · Since at least Sep 16, 2024
Rahul Singhvi
Other companies: Codexis, Inc. (Director · Since at least Sep 28, 2022)
Director · Since at least Dec 10, 2024
Doug SamuelsonChief Financial Officer · Since at least Nov 4, 2026
Hyun W. BaeDirector · Since at least Sep 16, 2024
John S. YuCEO & Chairman · Since at least Oct 6, 2026
Louie TomaInvestor Relations · May 6, 2025 – Nov 4, 2026 · Past
Michael KeyoungDirector · Since at least Nov 5, 2026
Neil BhowmickChief Scientific Officer · Since at least Nov 3, 2026
Rahul SingvhiDirector · Since at least Nov 5, 2026
Ramachandran MuraliVP of Research and Development · Since at least Oct 8, 2025
All 11 people
PersonSeat
Ramchandran MuraliVP, Research and Development · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Kairos Pharma, Ltd.